Yuhan Corporation

Gi Innovation, Inc.

Su Youn Nam

Jong Gyun Kim

Hyun Ho Choi

Minji Seo

Dohoon Kim

Young Jun Koh

Mi Kyeong Ju

Seul Gi Kim

Byung Hyun Choi

Jun Hwan Kim

Ju-Young Park

Seyoung Lim

Jun Kyung Lee

Dong Hoon Kim

Hyun Joo Lee

June Hyung Lee

Ju Young Park

Ki Hong Kim

Soo Yong Chung

Myung Ho Jang

Ge Hyeong Lee

Myoung Ho Jang

Kwan Hoon Hyun

Young-Gyu Cho

Na Rae Lee

Se Woong Oh

Tae Kyun Kim

Gyu Jin Lee

Ji Yeong Gal

Kyoung Kyu Ahn

Hyoung Sig Seo

Jun Chul Park

Seung Yub Shin

Tae-hoon Kim

Kaapjoo Park

Sangmyoun Lim

Hee Jong Lim

Ho Woong Kang

Su Jin Ahn

A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.

Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug

There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain

The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same

The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3&#x3b1; or CCL3&#x3b2; is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3&#x3b1; or CCL3&#x3b2; in the CCL3 variant.

Fusion protein comprising CCL3 variant and use thereof

The present invention provides a fused ring compound containing furan or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharmaceutical composition comprising same, and a use thereof. The fused ring compound containing furan or a pharmaceutically acceptable salt thereof inhibits the activity of phosphatidylinositol 3-kinase (PI3K) and can therefore be used in a pharmaceutical composition for treating and preventing respiratory diseases, inflammatory diseases, proliferative diseases, cardiovascular diseases, or central nervous system diseases which occur due to the over-activation of PI3K.

Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same

Growing community of inventors

Seoul, South Korea

Su Youn Nam